問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Otolaryngology

Division of Hematology & Oncology

Division of Thoracic Medicine

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Hematology & Oncology

National Taiwan University Cancer Center (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

廖斌志
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

239Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

廖斌志

List

350Cases

2018-06-01 - 2020-05-31

Phase I

Completed
A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation, and Expansion Study to Investigate the Safety, Pharmacokinetics, Food Effect, and Antitumor Activities of BGB-290 in Subjects with Advanced Solid Tumors

  • Condition/Disease

    For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment

  • Test Drug

    BGB-290

Participate Sites
5Sites

Terminated5Sites

2018-01-15 - 2029-06-30

Phase III

Active
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB(T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    KEYTRUDA

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting4Sites

2019-12-01 - 2024-12-31

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2020-01-01 - 2026-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2020-01-06 - 2026-01-31

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2020-03-01 - 2023-12-31

Phase I

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2020-04-01 - 2025-11-26

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting4Sites

Terminated1Sites

2020-04-01 - 2025-01-31

Phase I

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting2Sites

Terminated2Sites

2020-04-20 - 2024-11-01

Phase I

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2020-05-01 - 2024-04-15

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting9Sites

1 2 3 4 5 35
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB